Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Kopetz

Showing results (41-50 of 457) with videos related to

Pageof 46
Sort By:
Oncology (Williston Park, N.Y.)|October 19, 2022
Circulating Tumor DNA as a Marker of Minimal Residual DiseaseBen Fangman, Kanwal Raghav, Scott Kopetz
JAMA Oncology|May 10, 2019
Can Circulating Tumor DNA in Early-Stage Colorectal Cancer Be More Than a Prognostic Biomarker?Van Morris, Arvind Dasari, Scott Kopetz
The New England Journal of Medicine|February 27, 2020
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. ReplyScott Kopetz, Axel Grothey, Josep Tabernero
Future Oncology (London, England)|November 13, 2025
BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line <i>BRAF</i> V600E-mutant metastatic colorectal cancerScott Kopetz, Josep Tabernero, Elena Élez
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2018
Circulating Tumor DNA-Defined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant TherapiesArvind Dasari, Axel Grothey, Scott Kopetz
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2022
Truncal Dynamics May Trump: Serial ctDNA to Predict Early Therapeutic ResponseMadhulika Eluri, Scott Kopetz, Christine M Parseghian
Expert Opinion on Emerging Drugs|December 3, 2008
Emerging drugs for colorectal cancerDavid R Fogelman, Scott Kopetz, Cathy Eng
Nature Reviews. Clinical Oncology|July 11, 2019
Biomarker-guided therapy for colorectal cancer: strength in complexityAnita Sveen, Scott Kopetz, Ragnhild A Lothe
Journal of the National Cancer Institute|October 6, 2022
Diverticular disease and cancer risk: More than a gut feelingVeronika Fedirko, Scott Kopetz, Carrie R Daniel
Annals of Surgery|July 15, 2016
Addition of RAS Mutation Status May Strengthen the Predictive Model for Progression of Indeterminate Pulmonary NodulesYoshihiro Mise, Jean-Nicolas Vauthey, Scott Kopetz
Pageof 46

Showing results (41-50 of 457) with videos related to

Sort By:
Pageof 46
Oncology (Williston Park, N.Y.)|October 19, 2022
Circulating Tumor DNA as a Marker of Minimal Residual DiseaseBen Fangman, Kanwal Raghav, Scott Kopetz
JAMA Oncology|May 10, 2019
Can Circulating Tumor DNA in Early-Stage Colorectal Cancer Be More Than a Prognostic Biomarker?Van Morris, Arvind Dasari, Scott Kopetz
The New England Journal of Medicine|February 27, 2020
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. ReplyScott Kopetz, Axel Grothey, Josep Tabernero
Future Oncology (London, England)|November 13, 2025
BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line <i>BRAF</i> V600E-mutant metastatic colorectal cancerScott Kopetz, Josep Tabernero, Elena Élez
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2018
Circulating Tumor DNA-Defined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant TherapiesArvind Dasari, Axel Grothey, Scott Kopetz
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2022
Truncal Dynamics May Trump: Serial ctDNA to Predict Early Therapeutic ResponseMadhulika Eluri, Scott Kopetz, Christine M Parseghian
Expert Opinion on Emerging Drugs|December 3, 2008
Emerging drugs for colorectal cancerDavid R Fogelman, Scott Kopetz, Cathy Eng
Nature Reviews. Clinical Oncology|July 11, 2019
Biomarker-guided therapy for colorectal cancer: strength in complexityAnita Sveen, Scott Kopetz, Ragnhild A Lothe
Journal of the National Cancer Institute|October 6, 2022
Diverticular disease and cancer risk: More than a gut feelingVeronika Fedirko, Scott Kopetz, Carrie R Daniel
Annals of Surgery|July 15, 2016
Addition of RAS Mutation Status May Strengthen the Predictive Model for Progression of Indeterminate Pulmonary NodulesYoshihiro Mise, Jean-Nicolas Vauthey, Scott Kopetz
Pageof 46